Who Should Be Tested for Alpha-1 Antitrypsin Deficiency?

Alpha-1 antitrypsin deficiency is often remembered as a rare cause of emphysema in a young person who never smoked. That classic picture is useful, but too narrow. It misses older adults, people who have smoked, and people labeled as having asthma. It misses patients with bronchiectasis and those whose main problem is liver disease.

The COPD Foundation clinical practice guideline recommends testing all individuals with COPD regardless of age or ethnicity. It also recommends testing for unexplained chronic liver disease, unexplained bronchiectasis, and necrotizing panniculitis. It recommends testing for granulomatosis with polyangiitis and relatives of someone with an abnormal alpha-1 gene.

Testing matters because the diagnosis can change smoking and occupational counseling, family assessment, lung and liver monitoring, and eligibility for specific treatment. The test also carries genetic implications, so a good process explains what the result can and cannot tell your patient before you collect a sample.

What alpha-1 antitrypsin does#

Alpha-1 antitrypsin, often shortened to AAT, is a protein made mainly in the liver; it circulates in blood and protects lung tissue from enzymes released during inflammation, especially neutrophil elastase. When too little functional AAT reaches the lungs, protease activity can damage alveolar walls and contribute to emphysema.

The gene is SERPINA1. People inherit one allele from each biological parent, and the alleles are expressed codominantly. The common normal allele is often called M. The Z allele is the most important severe deficiency variant in many populations; S is another common deficiency allele. Null alleles produce no AAT, while some rare variants produce protein with abnormal function.

The liver problem follows a different mechanism from the lung problem. Some abnormal proteins, especially Z protein, misfold and accumulate inside hepatocytes. That gain-of-toxic-function can cause neonatal cholestasis, fibrosis, cirrhosis, or hepatocellular carcinoma. Null variants can create profound lung risk without the same protein-accumulation liver mechanism. That two-organ biology is why a normal chest history does not rule out a clinically important liver presentation, and why a low blood level does not by itself tell you every genetic risk.

Test all people with COPD#

The broadest practical recommendation is simple: everyone with COPD should be tested once. Restricting testing to early-onset disease, basilar emphysema, or absence of smoking misses cases. Smoking can be the factor that reveals inherited susceptibility rather than evidence against it.

Testing is appropriate whether COPD was diagnosed in primary care, pulmonary clinic, or during a hospital admission. A stable outpatient visit is often convenient because acute inflammation can raise AAT concentration, but a test can still be initiated during illness if you interpret the result carefully and repeat or confirm it as needed.

The diagnosis of COPD itself should rest on the clinical picture and post-bronchodilator spirometry, not on the AAT test, and a low level does not prove airflow obstruction, while a normal level does not reverse spirometric COPD. These are linked but separate questions. What finding AAT deficiency can change is what happens next: earlier family testing, smoking cessation support, avoidance of respiratory irritants, vaccination review, spirometric monitoring, liver assessment, and a discussion of augmentation therapy for selected patients.

Persistent obstruction labeled as asthma#

Asthma and COPD can overlap in symptoms, and labels often persist from earlier care; guidelines support AAT testing in adults with asthma whose airflow obstruction does not return to normal with appropriate treatment. The key issue is fixed or incompletely reversible obstruction, not the word written on the problem list.

Wheeze does not distinguish the conditions. People with AAT deficiency may wheeze during respiratory infections and can have bronchodilator responsiveness. A history of childhood symptoms or allergies also does not make inherited deficiency impossible. So when spirometry shows persistent obstruction, review smoking, inhaled irritants, and imaging. Review symptom course, eosinophilic features, bronchodilator response, and other causes. Include AAT testing among them. The result may add an etiology without replacing a full airway assessment.

Unexplained bronchiectasis#

Bronchiectasis describes permanently widened airways and has many causes, including prior infection, immune deficiency, and aspiration. Others are ciliary disorders, allergic bronchopulmonary aspergillosis, and genetic conditions. When the cause is unexplained, the COPD Foundation guideline recommends AAT testing.

The association is less common than classic emphysema, but identifying a heritable condition changes counseling and may clarify coexisting airflow obstruction. AAT testing should sit within a broader bronchiectasis workup rather than end it.

A normal serum concentration during an inflammatory flare deserves caution because AAT is an acute-phase reactant, and if clinical suspicion persists, genotype or phenotype testing and a later stable measurement can resolve uncertainty.

Chronic liver disease without an explanation#

People with unexplained chronic liver disease should be tested at any age. Possible presentations include abnormal liver enzymes, fibrosis, cirrhosis, portal hypertension, or hepatocellular carcinoma. In infants, prolonged cholestatic jaundice can be a clue.

The diagnostic workup should still consider viral hepatitis, alcohol-related disease, and metabolic dysfunction-associated steatotic liver disease. It should consider autoimmune disease, medicines, and hemochromatosis. It should consider Wilson disease when appropriate, and other causes. A SERPINA1 variant can coexist with another liver insult.

Protein phenotype can be more difficult to interpret in advanced liver disease or after transfusion. Molecular testing is often particularly helpful because it identifies inherited variants directly. Liver disease severity cannot be inferred from the AAT concentration alone.

Less common but important indications#

Necrotizing panniculitis is a rare inflammatory condition involving painful subcutaneous nodules that can ulcerate and release oily material, and its presence should prompt AAT testing, particularly when the course is severe or unexplained.

Granulomatosis with polyangiitis, formerly called Wegener granulomatosis, is another recommended testing setting. AAT interacts with proteinase-3 biology, and deficiency variants occur more often in some affected groups. Testing does not replace antineutrophil cytoplasmic antibody evaluation, tissue assessment, or vasculitis care.

A family pattern of early emphysema, otherwise unexplained liver disease, or respiratory impairment across generations should also raise suspicion, yet the absence of family history has little power to exclude the condition. Relatives may be undiagnosed, may have different environmental risks, or may carry variants with variable expression.

Relatives need an offer, not a prediction#

Parents, siblings, children, and sometimes extended family of a person with an abnormal AAT gene should be offered genetic counseling and testing; testing works best when the proband's variants are known, because relatives can receive targeted molecular analysis rather than relying on a serum level.

Genetic counseling should explain codominant inheritance, possible results, and variable disease expression. It should explain reproductive implications, privacy, and relevant insurance law. Rules differ by country and by insurance product. A general reassurance about genetic protection can be misleading.

Testing minors requires attention to the likelihood of actionable childhood benefit, family circumstances, and local ethics and law. Avoidance of tobacco smoke and recognition of liver disease can be relevant early, but the process should protect the child's interests and future autonomy.

Relatives should not be told that an allele guarantees emphysema or cirrhosis. Genotype changes probability. Smoking, dusts and fumes, and infections shape outcome. So do other liver injury, age, and biological variation.

Why the serum level can mislead#

A quantitative AAT level is a logical first component, but it has limits. AAT rises during systemic inflammation, infection, pregnancy, and some estrogen states; a person with a deficiency allele can therefore have a result closer to the reference interval during an acute inflammatory episode.

Laboratories also use different assays and units. Do not apply a cutoff copied from one source without your laboratory's method and reference interval: the commonly cited severe-deficiency threshold near 11 micromoles per liter, often approximated as 57 mg/dL by nephelometry, is not a universal conversion across assays.

Serum concentration is particularly weak for identifying carrier status because ranges overlap. A person with an MZ or MS genotype may have a concentration within a laboratory's normal interval. Rare variants can also create functional deficiency with a quantitatively normal level. GeneReviews notes that the F variant can impair elastase binding without necessarily producing a low concentration, which is why many diagnostic pathways combine a serum concentration with genotyping for at least S and Z alleles, and why protein phenotype can add information about circulating forms.

How to build a reliable testing sequence#

Start with a quantitative serum AAT concentration and a genetic assay that detects common clinically important alleles, usually at least S and Z. Record whether the patient is acutely ill and consider a marker of inflammation or a repeat level after recovery when your interpretation is uncertain.

If the level, genotype, protein phenotype, and clinical presentation agree, the diagnosis may be straightforward. A very low level with no S or Z allele is not a negative result; it is a reason to investigate null or rare variants. A normal level with a suspicious phenotype can also justify expanded testing.

Confirmatory options include protein phenotyping by isoelectric focusing, expanded SERPINA1 genotyping, sequencing, and deletion or duplication analysis. The appropriate sequence depends on your local laboratory's capability and the question you are asking.

Do not label a person solely from one screening card without confirming identity, assay quality, and the result. Conversely, do not let a preliminary abnormal result disappear into the record without a closed follow-up plan.

What a positive result does not decide#

A positive genetic result does not establish that current breathlessness comes from AAT deficiency. Symptoms still need spirometry, oxygen assessment when indicated, and imaging. They need cardiac evaluation and consideration of other pulmonary causes.

It also does not automatically mean intravenous augmentation therapy is appropriate. Eligibility generally depends on severe deficiency, established airflow obstruction, and smoking status. It generally depends on clinical range, product approval, and payer or national criteria. Augmentation aims to raise circulating protective protein; it does not treat liver protein accumulation and is not a cure.

Some genotypes carry modest or uncertain risk. An MZ result, for example, often calls for strong prevention and clinical context rather than treatment as if it were ZZ disease. Interpretation should use genotype-specific evidence.

Care after diagnosis#

The most powerful lung intervention is avoiding tobacco smoke. People should also reduce contact with occupational dust, fumes, and pollutants when feasible. Vaccination and prompt management of respiratory infections are part of ordinary COPD and chronic lung care.

Baseline and follow-up spirometry help track airflow. Imaging is guided by symptoms and clinical need rather than repeated on an automatic schedule. Liver monitoring commonly includes history, examination, and laboratory tests. It includes imaging based on genotype, age, findings, and specialist guidance.

Family communication needs a plan. The diagnosed person can be offered a letter that explains the familial result without disclosing more medical detail than necessary. Relatives can then seek their own counseling and testing.

The diagnosis should be recorded accurately, including genotype, phenotype when available, and assay. The record should also give level with units and date. “Alpha-1 carrier” without the actual variants is often too vague for future decisions.

References#

1. COPD Foundation clinical practice guideline on alpha-1 antitrypsin deficiency
2. GeneReviews on alpha-1 antitrypsin deficiency
3. European Respiratory Society statement
4. ATS and ERS standards
5. GOLD 2026 COPD report
6. Alpha-1 Foundation testing and diagnosis resources